Oxidative stress is implicated in the pathogenesis of pulmonary damage during viral infections. In a previous study we observed a significant improvement of survival of influenza-infected mice with NAC , 191kg divided in two daily administrations, for 8 days including a pretreatment on day 1 before infection.In order to test NAC in a more realistic model, we studied the effect of combined treatment with NAC and the antiviral drug, ribavirin. Since in the present work we wanted to test a possible synergistic effect by combination of NAC and ribavirin, we used a different NAC's treatment regimen (1 g/kg, once a day for 4 days) that, alone, did not significantly protect mice from death. Mice (12 per group) infected intranasally with a lethal dose of influenza A virus APR/8. NAC was given as a single daily dose of 1000 mglkg starting from 4 h after infection and until day 4 after infection, in association with ribavirin (100 mglkg, ip), Endpoint evaluation was 14-day survival. With this schedule survival in infected mice was 17%, it was not significantly changed by NAC (25%). Survival increased to 58% with ribavirin and to 92% (n=12) with a combined treatment with ribavirin and NAC. This suggest that antioxidant therapy can increase survival by either improving the defenses against virus or by protecting from the pathogenesis oflung inflammation.
Influenza virus, the causati ve agent of common flu, induces pulmonary damage by a variety of mechanism one of which is mediated by oxidative stress. In fact, it was shown that influenza infected mice have lower levels of the antioxidant glutathione (GSH) in the lung (I), and an induction of the superoxide-generating enzyme xanthine oxidase (2, 3) . Many data showed a protective effect of the xanthine oxidase inhibitor, allopurinol, or the antioxidant enzyme superoxide dismutase in animal models (2) indicating the importance of oxidative stress in the pathogenesis of influenza. Recent data also indicate that transgenic mice overexpressing the antioxidant enzyme thioredoxin are resistant to influenza virus-induced pneumonia (4) . It is noted that oxidative stress is not restricted to influenza, as it was reported in other common viral infections, including rhinovirus infection (5, 6) , as well as in AIDS (7) (8) and possibly in other respiratory infections. In addition to contribution to the pathogenesis of pulmonary damage, reactive oxygen intermediates can be implicated for some of their complications, as airway hyperresponsiveness, directly or indirectly through the production of cytokines (9) .
An analysis using DNA microarrays of the gene expression has shown that influenza induces several genes as a response to stress and many cytokines (10) . Induction of inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin (IL)-6, has also been documented in vivo, and in part can be related to oxidative stress. In fact, oxidative stress contributes to induction of cytokines such as TNF, IL-8, MCP-l, and in vivo, the glutathione precursor and antioxidant, Nacetylcysteine (NAC) inhibits the production of cytokines in other animal models, such as those of endotoxicosis (11).
These studies have prompted the testing of the hypothesis that NAC could ameliorate the disease in clinical settings and in animal models. Our group reported that N AC improves survival in mice lethally infected with influenza virus (3), while a clinical study reported that oral NAC treatment ameliorates symptoms and immunological parameters in patients with influenza infection (12) . In fact, the improvement of cell-mediated immunity observed with NAC in influenza patients suggests that aSH may act not only by inhibiting the overproduction of inflammatory cytokines, and in fact it was shown that aSH is essential for lymphocyte functions (13) .
While we previously reported that NAC alone is protective in a model oflethal influenza infection were not realistic as in that model NAC was administered alone and with a pretreatment schedule (3) . The aim of this work was thus to investigate the effect of combined treatment with NAC and ribavirin, in a mouse model of lethal influenza infection. In fact, in a clinical setting of a viral disease, the patients would likely undergo treatment with antiviral agents.
MATERIALS AND METHODS
Male, adult (18-20 g) CDI mice were obtained from Charles River Italia, Calco, Italy; infections were carried out at Zambon R&D Department. Mice (12 per treatment group) were anesthetized under ether/ chloroform (70%/30%) and infected intranasally with 2-3 LD50 of viral suspension in 0.05 ml of tryptose broth. The virus used was influenza A, strain PRl8, obtained from American Type Culture Collection, Rockville, MD. NAC (Zambon Italia, Bresso, Italy) was administered as single daily dose of 1000 mg/kg by oral gavage. Ribavirin (Sigma-Aldrich S.r.l., Milano) was given at the daily dose of 100 mg/kg, i.p. Control mice received vehicle alone. Treatments were started 4 h after infection and continued until day 4 after infection. Survival was monitored daily until day 14. Survival curves were compared by the Log-Rank test.
RESULTS
In our previous study (3) we observed a significant improvement of survival of influenza- Days infected mice with NAC administered twice daily, for 8 days including a pretreatment on day 1 before infection. Since in the present work we wanted to evidentiate a possible synergy between NAC and ribavirin, we used a different NAC's treatment schedule (1 g/kg, once a day for 4 days) that, alone, did not significantly protect mice from death. Furthermore, to more closely resemble a clinical condition, no pretreatment dose was given. As shown in Figure 1 , With this schedule survival in infected mice was 17%, it was not significantly changed by NAC (25%). Survival increased to 58% with ribavirin and to 92% (n=12) with a combined treatment with ribavirin and NAC. From the survival curve, it is clear that death rate is also slower in the NAC/ribavirin group. The effect of NAC+ribavirin was statistically significant (P<0.05 by Log-rank test versus control).
DISCUSSION
The synergistic effect of the two drugs supports the idea that they do not act through the same mechanism. In fact, we had previously reported (3) that NAC does not affect influenza virus replication, and it is conceivable that NAC, as it known for other models of lung disease, such as in models of acute respiratory distress syndrome (ARDS), may act on the pathogenesis of the disease, particularly when this involves production of reactive oxygen intermediates and cytokines. This hypothesis is based on an extensive literature showing that NAC inhibits the induction of several genes implicated in inflammation, including several cytokines, through inhibition of transcription factors AP-1 andNF-kappaB (14) . In a model of peritoneal sepsis associated with pulmonary inflammation, NAC inhibits the inflammatory infiltrate in the lung but does not inhibit the antibacterial response in the peritoneum, indicating that antioxidants might redirect the immune response in a way more favorable to the host (15), an effect that might be, at least in part, mediated via IL-10, as shown with other antioxidants in the same model (16) . Inflammatory cytokines can also impair host defense against influenza, as a recent work shows that IL-18 knockout mice infected with influenza virus show less inflammatory response and increased viral clearance (17) .
On the other hand, clinical studies have shown NAC also improved the disease in patients with common, non-complicated, influenza (12) . One possibility is that NAC also improves the immune function in conditions of oxidative stress, as it was shown for HIV patients (18, 19) . In addition, although in the present study we have used a nontoxic dose of ribavirin, it is important to note that one of the main toxic effects of this drug is the induction of hemolytic anemia, which is probably mediated by oxidative damage (20) (21) . Thus, the effectiveness of NAC on top of that of ribavirin in a lethal model of infection suggests that NAC might ameliorate the therapeutic index of ribavirin, either by decreasing its roxicity or allowing the use of a lower dose of drug. Our data suggest the possibility that a aSH-replenishment therapy with thiol antioxidant might be useful in other viral diseases.
